Arcturus Therapeutics Holdings Inc.

NasdaqGM:ARCT Stock Report

Market Cap: US$612.6m

Arcturus Therapeutics Holdings Valuation

Is ARCT undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of ARCT when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

US$72.17
Fair Value
68.7% undervalued intrinsic discount
10
Number of Analysts

Below Fair Value: Insufficient data to calculate ARCT's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate ARCT's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for ARCT?

Key metric: As ARCT is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for ARCT. This is calculated by dividing ARCT's market cap by their current revenue.
What is ARCT's PS Ratio?
PS Ratio5x
SalesUS$122.12m
Market CapUS$612.61m

Price to Sales Ratio vs Peers

How does ARCT's PS Ratio compare to its peers?

The above table shows the PS ratio for ARCT vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average7x
GYRE Gyre Therapeutics
6.6x16.99%US$673.0m
MGTX MeiraGTx Holdings
17.9x43.14%US$679.8m
ORGO Organogenesis Holdings
1.3x17.99%US$544.2m
CDNA CareDx
2.4x11.69%US$808.5m
ARCT Arcturus Therapeutics Holdings
5x38.20%US$612.6m

Price-To-Sales vs Peers: ARCT is good value based on its Price-To-Sales Ratio (5x) compared to the peer average (7x).

Price to Sales Ratio vs Industry

How does ARCT's PS Ratio compare vs other companies in the US Biotechs Industry?

158 CompaniesPrice / SalesEstimated GrowthMarket Cap
AMGN Amgen
4.6x2.13%US$160.37b
GILD Gilead Sciences
4.8x4.47%US$139.83b
REGN Regeneron Pharmaceuticals
4.4x6.25%US$62.21b
BIIB Biogen
2.3x-1.17%US$23.44b
ARCT 5.0xIndustry Avg. 10.5xNo. of Companies158PS020406080100+
158 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: ARCT is good value based on its Price-To-Sales Ratio (5x) compared to the US Biotechs industry average (10.5x).

Price to Sales Ratio vs Fair Ratio

What is ARCT's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

ARCT PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio5x
Fair PS Ratio1.7x

Price-To-Sales vs Fair Ratio: ARCT is expensive based on its Price-To-Sales Ratio (5x) compared to the estimated Fair Price-To-Sales Ratio (1.7x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst ARCT forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$22.56
US$68.90
+205.41%
43.47%US$140.00US$42.00n/a10
Sep ’26US$17.01
US$69.89
+310.88%
44.95%US$140.00US$42.00n/a9
Aug ’26US$12.30
US$67.40
+447.98%
46.36%US$140.00US$35.00n/a10
Jul ’26US$12.99
US$67.40
+418.87%
46.36%US$140.00US$35.00n/a10
Jun ’26US$12.53
US$66.80
+433.13%
47.56%US$140.00US$32.00n/a10
May ’26US$12.50
US$70.30
+462.41%
41.75%US$140.00US$44.00n/a10
Apr ’26US$9.43
US$73.10
+675.20%
38.38%US$140.00US$44.00n/a10
Mar ’26US$16.79
US$76.32
+354.56%
37.26%US$140.00US$44.00n/a10
Feb ’26US$16.97
US$75.62
+345.62%
38.62%US$140.00US$41.00n/a10
Jan ’26US$16.97
US$79.47
+368.28%
35.58%US$140.00US$44.00n/a9
Dec ’25US$18.34
US$79.47
+333.30%
35.58%US$140.00US$44.00n/a9
Nov ’25US$18.00
US$77.26
+329.23%
33.93%US$140.00US$44.00n/a9
Oct ’25US$25.25
US$77.26
+205.99%
33.93%US$140.00US$44.00US$20.489
Sep ’25US$21.10
US$77.26
+266.17%
33.93%US$140.00US$44.00US$17.019
Aug ’25US$21.58
US$74.75
+246.39%
36.58%US$140.00US$48.00US$12.308
Jul ’25US$23.66
US$74.75
+215.93%
36.58%US$140.00US$48.00US$12.998
Jun ’25US$38.81
US$72.25
+86.16%
39.40%US$140.00US$48.00US$12.538
May ’25US$27.91
US$67.93
+143.38%
46.62%US$140.00US$18.00US$12.509
Apr ’25US$33.08
US$67.93
+105.34%
46.62%US$140.00US$18.00US$9.439
Mar ’25US$39.73
US$66.33
+66.96%
48.41%US$140.00US$18.00US$16.799
Feb ’25US$34.67
US$65.44
+88.76%
49.98%US$140.00US$18.00US$16.979
Jan ’25US$31.53
US$65.44
+107.56%
49.98%US$140.00US$18.00US$16.979
Dec ’24US$24.87
US$63.50
+155.33%
53.86%US$140.00US$18.00US$18.348
Nov ’24US$18.77
US$60.56
+222.62%
54.25%US$140.00US$18.00US$18.009
Oct ’24US$25.55
US$60.56
+137.01%
54.25%US$140.00US$18.00US$25.259
US$68.9
Fair Value
67.3% undervalued intrinsic discount
10
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/10/05 02:05
End of Day Share Price 2025/10/03 00:00
Earnings2025/06/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Arcturus Therapeutics Holdings Inc. is covered by 26 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Huidong WangBarclays
Mayank MamtaniB. Riley Securities, Inc.
Thomas ShraderBTIG